Cancer Moonshot Initiative

Last week I participated in the AAADV Workshop (Accelerating Anticancer Agent and Development and Validation.) Leaders in clinical and translational cancer research from academia, industry, government and the nonprofit advocacy sectors convene each spring in Bethesda, Maryland, for a unique forum designed to speed cancer treatments to patients. The three and one-half day, on-site interactive AAADV Workshop offers a mix of small group lectures, moderated discussions, plenary lectures and facilitated case studies of successful drug applications. Participants gain valuable insights on negotiating the spectrum of successful drug development and hone their strategic planning skills with a focus on target validation and pathway identification. The AAADV is the only workshop held in collaboration with the U.S. Food and Drug Administration designed specifically to help, participants understand and negotiate the drug development approval process so that effective cancer treatments can reach patients more quickly.
Participants Will:
Examine the most urgent issues and meaningful trends in anticancer agent development and
validation.
Learn new approaches for diagnosing, treating and preventing cancer.
Benefit from a mix of small group lectures, moderated discussions, facilitated case studies of
successful new drug applications and plenary lectures.
Network with researchers, regulators, patient advocates and others working on the frontlines of
cancer research and treatment.
Rather than my trying to piece together the welcome speech by Moonshot Director Greg Simon, executive director of the cancer moonshot task force, I thought to give you the link to the Cancer Letter, which is written by a journalist with with excellent writing skills. Here we go:
http://www.cancerletter.com/articles/20160506_2